All Updates

All Updates

icon
Filter
Funding
Prolight Diagnostics receives UK Government grant to develop Psyros point-of-care test for cardiac arrest
Precision Medicine
May 21, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 21, 2024

Prolight Diagnostics receives UK Government grant to develop Psyros point-of-care test for cardiac arrest

Funding

  • Prolight Diagnostics has received SEK 17 million (~USD 16.1 million) as a grant from the i4i Product Development Awards sponsored by the National Institute for Health and Care Research, UK.

  • The funds are expected to support a pre-validation study at St. Thomas’ Hospital to evaluate the performance of the company’s Psyros point-of-care test for cardiac arrest before the clinical trials in 2025.

  • Sweden-based Prolight Diagnostics specializes in developing point-of-care systems for in-vitro diagnostic (IVD) testing. Its flagship technology, Psyros, is a digital immunoassay platform capable of single-molecule counting. It is primarily used to detect cardiac biomarkers like troponin, with future applications in development for other biomarkers. Psyros allows the detection of low levels of troponin, released into the bloodstream during a heart attack, for early detection of heart attacks and prioritizing patients according to criticality.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.